Solstice (SOLS) Q2 2026 earnings review
Top-Line Acceleration with an Aggressive Pivot to M&A
Solstice delivered a strong Q2 with 11% YoY revenue growth, propelled by secular tailwinds in Nuclear and Electronic Materials, alongside a sharp reversal in Healthcare Packaging demand. While Net Income surged 23% to $119M, the underlying margin story is mixed: Adjusted EBITDA margins contracted 218 bps YoY to 25.3%, weighed down by the HFO transition and plant turnarounds in the RAS segment. Management expressed immense confidence by raising full-year guidance and announcing a transformational acquisition of Element Solutions. However, the math beneath the raised sales guidance reveals an implied deceleration in the back half of the year.
🐂 Bull Case
Nuclear (+27%) and Electronic Materials (+15%) continue to post robust, sustainable double-digit growth driven by AI, data center buildouts, and energy transition.
Healthcare Packaging has successfully navigated its inventory correction, accelerating from a 25% decline in 25Q4 to a powerful 24% YoY growth this quarter.
🐻 Bear Case
Refrigerants & Applied Solutions margins plunged 648 bps to 32.9% due to plant turnaround timing and the ongoing margin friction from the HFC-to-HFO product mix shift.
Building Solutions remains the clear laggard, dropping 1% YoY as persistent softness in global construction markets offsets the tech-driven growth.
⚖️ Verdict: 🟢
Bullish. The organic growth engine is accelerating, and the Element Solutions acquisition is a bold, offensive move to build a scaled advanced materials platform. If management can deliver the promised margin recovery in H2, the stock has room to run.
Key Themes
Transformational Pivot to M&A: Element Solutions
The announcement of the cash-and-stock acquisition of Element Solutions marks a major strategic shift from post-spin stabilization to aggressive inorganic scaling. Expected to close in H1 2027, the deal explicitly targets secular mega-trends: AI, data centers, nuclear energy, and semiconductor manufacturing, expanding Solstice's TAM significantly.
Healthcare Packaging Demand Reversing
After a painful destocking cycle, Healthcare Packaging has firmly reversed trajectory. The segment accelerated from +9% in 26Q1 to a robust +24% YoY growth ($73M) in Q2. This provides a fresh, normalized growth engine alongside the company's tech drivers.
Advanced Semiconductors Fueling Electronic Materials
Electronic Materials grew 15% to $119M, driven heavily by specific technological innovation: demand for advanced copper manganese sputtering targets required for leading-edge, sub-7nm semiconductor manufacturing nodes. This directly ties Solstice to the core infrastructure of the AI buildout.
RAS Margin Compression Contradicts Top-Line Growth
A concerning divergence exists within the RAS segment. Despite revenue accelerating to 12% YoY growth, Adjusted EBITDA actually dropped 6%. The margin collapsed 648 bps to 32.9% due to plant turnaround timing and prior-year production credits. While management projects a return to mid-30% in H2, the current margin erosion contradicts the top-line beat.
Building Solutions Lags the Portfolio
In stark contrast to the rest of the portfolio, Building Solutions & Intermediates continues to struggle. Sales declined 1% YoY to $180M, continuing a string of weak quarters (down 8% in Q1) due to persistent softness in the housing and commercial construction end-markets.
Standalone Corporate Expenses Escalating
The friction of operating as an independent company post-spin remains highly visible. Corporate expenses climbed to $54M in Q2, up from $46M a year ago. The integration of Element Solutions will likely add further complexity and cost to this line item.
Divergent Macroeconomic Indicators
Solstice is operating a two-speed portfolio. Strong AI and data center cap-ex tailwinds are insulating the ESM and Nuclear segments, contrasting sharply with the stagnant industrial and commercial construction macros dragging down the Building Solutions business.
Other KPIs
Stable. Operating Cash Flow of $461M easily funded elevated capital expenditures of $186M (+35% YoY to support growth expansions). At a 1.3x net leverage ratio, the balance sheet provides ample dry powder for the upcoming Element Solutions acquisition.
Accelerating. Up 280 bps YoY, driven directly by volume growth and high operating leverage within the Electronic Materials and Safety & Defense subdivisions.
Guidance
Decelerating implicitly. While management technically raised the full-year target, the underlying math implies a sharp H2 slowdown. H1 generated $2.14B (+10.8% YoY). The new midpoint ($4.155B) requires only $2.01B in H2—implying YoY growth drops to approximately 3% in the back half of the year.
Decelerating. The midpoint of $1,010M implies a steep sequential drop of 12% from Q2's robust $1,148M, and represents a mild 4.2% YoY growth vs 25Q3, confirming the H2 top-line slowdown.
Accelerating profit momentum. Raised from $975-$1,025M. While sales growth is slowing, H2 implied EBITDA of ~$506M represents roughly 19% YoY growth against a weak H2 2025. This supports management's claim that RAS margins will rebound to the mid-30% range by year-end.
Key Questions
H2 Revenue Deceleration
You raised full-year sales guidance, but the math implies a sharp deceleration to roughly 3% YoY growth in H2. Is this simply conservative forecasting, or are you seeing order book softness in specific end markets for the back half?
RAS Margin Recovery Bridge
RAS margins fell 648 bps YoY to 32.9%. You expect a return to the mid-30% range in H2. What specific catalysts—such as the absence of turnaround costs or an inflection in the HFO aftermarket—bridge that sequential margin recovery?
Element Solutions Integration and Leverage
With the Element Solutions acquisition targeted for H1 2027, can you provide early color on expected run-rate cost synergies and the pro-forma net leverage profile you anticipate upon closing?
Building Solutions Floor
Building Solutions contracted 1% this quarter after an 8% drop in Q1. Are we at the bottom of the destocking and macro-driven weakness, or is there risk of further deterioration in commercial construction demand?